Current Cancer Drug Targets
Title:Meet Our Editorial Board Member:
Volume: 16 Issue: 3
Author(s): Ingunn Holen
Affiliation:
Export Options
About this article
Cite this article as:
Holen Ingunn, Meet Our Editorial Board Member:, Current Cancer Drug Targets 2016; 16 (3) . https://dx.doi.org/10.2174/156800961603160206121939
DOI https://dx.doi.org/10.2174/156800961603160206121939 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
17
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Exciting Potential of Nanoparticlized Lipidic System for Effective Treatment of Breast Cancer and Clinical Updates: A Translational Prospective
Current Pharmaceutical Design Intercalators as Anticancer Drugs
Current Pharmaceutical Design How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Genetic Instability Influences Drug Response in Cancer Cells
Current Drug Targets Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology The Economics of Pharmacogenomics
Current Pharmacogenomics CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Editorial (Thematic Issue: Crosstalk Between the Nervous and the Immune Systems in Health and Sickness)
Current Pharmaceutical Design Oleocanthal, a Natural anti-Inflammatory Compound in Extra Virgin Olive Oil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets <i>In Vivo</i> Tracking of Novel SPIO-Molday ION Rhodamine-B™-Labeled Human Bone Marrow-Derived Mesenchymal Stem Cells After Lentivirus- Mediated COX-2 Silencing: A Preliminary Study
Current Gene Therapy Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Proteomic Analysis of Medicinal Plant <i>Calotropis Gigantea</i> by <i>In Silico</i> Peptide Mass Fingerprinting
Current Computer-Aided Drug Design